Prenumeration
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
On November 17th, Genetic Analysis AS (“Genetic Analysis” or the “Company”) announced a milestone for the Company’s ongoing IBD Precision Dx project, where the biomarker panel development now has been completed. This means that the next and final step before launch, expected in H1-26, is the final validation phase and completion of software development.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Genetic Analysis. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.